C-U2WKMitochem Therapeutics
small molecules, mitochondrial dysfunction, cellular metabolism
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-U2WK
C-U2WKC-U2WKsmall molecules, mitochondrial dysfunction, cellular metabolism
0-100 chain-logic scale · 15 dimensions · scored on public evidence
MitoChem Therapeutics states that mitochondrial dysfunction is a key driver of ocular and other neurodegenerative diseases and that mitochondrial protective therapeutics can address these conditions. The company presents its work as developing treatments for hard-to-treat neurodegenerative diseases, especially those causing vision loss such as retinitis pigmentosa, age-related macular degeneration, and glaucoma.
SourceMitoChem Therapeutics states that mitochondrial dysfunction is an important driver of neurodegenerative disease and that mitochondrial-protective therapeutics can be developed to address its effects, particularly in ocular disorders. The company presents its compounds as promising treatments for vision loss in retinitis pigmentosa, age-related macular degeneration, and glaucoma, with the overarching goal of preserving sight.
SourceMitoChem Therapeutics states that mitochondrial dysfunction is a key driver of neurodegenerative disease and that developing mitochondrial-protective therapeutics can help treat ocular and neurodegenerative conditions, with a particular emphasis on preserving vision in diseases such as retinitis pigmentosa, age-related macular degeneration, and glaucoma.
SourceMitoChem Therapeutics states that mitochondrial decline is linked to degenerative diseases such as retinitis pigmentosa and age-related macular degeneration, and that targeted small-molecule compounds may slow this decline and thereby slow disease progression, potentially preserving vision for patients for several additional years.
Source